ANI Pharmaceuticals Inc.
Rating
Updated: Aug 27, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides i...
Latest News
8 days ago · seekingalpha.com
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
29 days ago · globenewswire.com
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026.
1 month ago · defenseworld.net
Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIPAurora Investment Counsel bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) in the undefined quarter, according to its most recent filing with the SEC. The fund bought 26,890 shares of the specialty pharmaceutical company's stock, valued at approximately $2,226,000. Aurora Investment Counsel owned 0.12% of ANI Pharmaceuticals at the end of
1 month ago · zacks.com
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half GrowthCortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.
1 month ago · zacks.com
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
1 month ago · zacks.com
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View CutANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.
2 months ago · seekingalpha.com
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call TranscriptANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
2 months ago · zacks.com
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key MetricsWhile the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
2 months ago · marketbeat.com
ANI Pharmaceuticals Q2 Earnings Call HighlightsANI Pharmaceuticals NASDAQ: ANIP reported record second-quarter revenue and adjusted EBITDA as growth in its Cortrophin Gel rare-disease franchise and generics business lifted results, while the company modestly reduced its full-year Cortrophin revenue outlook to reflect first-half performance.
2 months ago · zacks.com
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat EstimatesANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $1.8 per share a year ago.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ANIP